Publication | Closed Access

Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Cell TherapyCytomegalovirus InfectionTransplantationStem Cell TransplantationGraft SurvivalMedicineCell TransplantationHaematopoietic Stem-cell Transplantation